A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center

Manju Sengar; A Akhade; R Nair; H Menon; T Shet; S Gujral; E Sridhar; S Laskar; M Muckaden

doi:10.4103/0971-5851.95140

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(04): 197-203
DOI: 10.4103/0971-5851.95140

ORIGINAL ARTICLE

A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center

Manju Sengar

Department of Medical Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

A Akhade

Department of Medical Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

R Nair

Department of Medical Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

H Menon

Department of Medical Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

T Shet

Department of Pathology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

S Gujral

Department of Pathology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

E Sridhar

Department of Pathology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

S Laskar

Department of Radiation Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

,

M Muckaden

Department of Radiation Oncology, Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

› Institutsangaben

Abstract

als PDF herunterladen

Abstract

Background: The uniqueness of adolescent and young adult (AYA) non-Hodgkin lymphomas (NHL) with respect to biology and treatment have largely remained unanswered due to marked heterogeneity in treatment, paucity of prospective, or retrospective studies and poor representation of AYA in clinical trials. This audit attempts to put forward the clinicopathological attributes and treatment outcomes of AYA NHL treated with both pediatric and adult protocols from a single centre in a developing country. Patients and Methods: Hospital records of all consecutive NHL patients registered in lymphoma clinic from January 2007 to May 2010 were reviewed for information on demography, clinical features, histology subtype, staging, treatment regimen, response rates, toxicities, and follow up. Two-year progression-free (PFS) and overall survival (OS) were calculated with Kaplan-Meier method. Results: AYA NHL constituted 4% of all lymphomas. Diffuse large B-cell (DLBL) was the most frequent subtype. Following were the 2-year PFS and OS - DLBL 64%, 76.9%, Burkitt′s lymphoma: 56%, 56%, lymphoblastic lymphoma: 33.2%, 44%. Our results did not show any improvement in outcome of DLBL with the use of Burkitt′s lymphoma like regimen. Conclusions: This study highlights some of the key features of AYA NHL occurring in developing world.

Keywords

Adolescent and young adults - adolescent and young adults malignancies - non-Hodgkin lymphoma

PDF (775 kb)

Referenzen

References
1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics 2009. CA Cancer J Clin 2009;59:225-49.
2 O′Leary M, Sheaffer J, Keller F, Shu XO, Cheson B. Lymphomas and reticuloendothelial neoplasms. In: Bleyer A, O′Leary M, Barr R, Ries LA, editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006.
3 Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 2005;35:182-217.
4 Harris NL, Swerdlow SH, Jaffe ES, et al.. WHO classification of tumors of hematopoietic and lymphoid tissues. Vol. 4. Lyon: International Agency for Research on Cancer: 2008.
5 Advani S, Pai S, Adde M, Vaidya S, Vats T, Naresh K, et al. Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin′s lymphoma in India. Ann Oncol 1997;8:893-7.
6 Raje SN, Vaidya SJ, Kapoor G, Pai SK, Nair CN, Kurkure PA, et al. Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. Indian Pediatr 1996;33:556-60.
7 Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol 2009;36:381-418.
8 Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin′s lymphoma. N Engl J Med 1993;328:1002-6
9 Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster group trial NHL-BFM - 90. Blood 1999;94:3294-306.
10 Moleti ML, Testi Am, Giona F, Malandruccolo L, Pescarmona E, Martino P, et al. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitts Leukemia/Lymphoma amd large B-cell lymphomas: A 15-year monocentric experience. Leuk Lymph 2007;48:551-9.
11 Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-20.
12 Thomas DA, Cortes J, O′Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt′s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-70.
13 Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-Cell lymphoblastic lymphoma: A BFM group report. Blood 2000;95:416-21.
14 Hoelzer D, Gokbuget N, Diget W, Faak T, Kneba M, Reutzel R, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002;99:4379-85.
15 Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR; et al. Anaplastic large cell lymphoma in childhood: Analysis of 72 patients treated on the United Kingdom Children′s Cancer Study Group chemotherapy regimens. Br J Haematol 2002;117:812-20.
16 Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non-Hodgkins lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster group trial NHL-BFM-90. Blood 2001;97:3699-706.
17 Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of Children′s Cancer Group study 5941. Pediatr Blood Cancer 2009;52:335-9.
18 Fanin R, Sperotto A, Silvestri F, Cerno M, Geromin A, Stocchi R, et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: Results of 40 cases treated in a single center. Leuk Lymph 1999;35:159-69.